Gabapentin Capsule
Product Images NDC 71335-1169

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1169). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration depicting the calculation formula for creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and a correction factor for female patients. The formula is shown as a fraction with the numerator and denominator specified, including the multiplication by 0.85 for females.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain score over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Gabapentin demonstrates a decrease in mean pain score over time, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line graph showing mean pain scores over seven weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show lower mean pain scores than placebo throughout the study period.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. The vertical axis shows percentage responders from 0% to 100%. Study 1 compares PBO (12%) and GBP 3600 mg (29%). Study 2 compares PBO (14%) with GBP 1800 mg (32%) and GBP 2400 mg (34%). Statistical significance is indicated with p-values <0.01 and <0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart showing percentage difference on the y-axis against daily dose in mg on the x-axis for gabapentin at doses 600, 900, 1200, and 1800 mg. Data points represent three different studies labeled as Study a, Study b, and Study c with distinct markers and are plotted to compare difference percentages for each daily dose.*

FDA Label Image

Label (Lbl713351169)

Gabapentin 100 mg capsule label from Bryant Ranch Prepack. The label displays the product name and strength prominently, with storage instructions (20°-25°C/68°-77°F) and warnings including dizziness and keeping drugs out of reach of children. It includes a comparison to Neurontin 100 mg capsule and a barcode, with the NDC 71335-1169 visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.